GlassScriptPhysician profile
Keith C Barkow
NPI 1891767372
$5,184.54
in general payments reported to CMS, 2019-2025
38 companies · $679 in 2025
The $679 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $407 · 2021: $1,123 · 2022: $437 · 2023: $691 · 2024: $1,300 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,651 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,651.38 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $812.33 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $617.28 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $511.51 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $334.68 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $322.25 | 2022-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $230.06 | 2019-2025 | Glassia, Trintellix |
| Astrazeneca Pharmaceuticals LP | $212.71 | 2020-2024 | Airsupra |
| Glaxosmithkline, LLC. | $205.80 | 2019-2025 | Trelegy Ellipta, Penmenvy |
| Sanofi Pasteur INC. | $204.91 | 2019-2025 | |
| Amgen INC. | $195.91 | 2021-2025 | Evenity, Prolia, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.25 | 2019-2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $120.04 | 2021 | |
| Organon LLC | $109.54 | 2022-2025 | Jada System, Nexplanon |
| Janssen Pharmaceuticals, INC | $84.50 | 2019-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $75.29 | 2023-2024 | Rexulti |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Barkow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.